GNS Genus plc
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Genus (LON: GNS)
›
Genus (LON: GNS) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,921 employees.
The shares were at 2126.00 GBp on 19 November 2026, down 10.9% over 52 weeks. Its 52-week range is 1943.00 GBp to 3220.00 GBp: the price is 34.0% below the high and 9.4% above the low.
At a market capitalisation of 1.37B GBP, it trades at 5.0 times trailing earnings and 18.3 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 85% for GNS. It pays a dividend yielding 1.63% (it pays out 8% of its earnings), against a median of 0.94% among the dividend payers in that peer group.
Genus reports return on equity of 37.2%, an operating margin of 12.0% and revenue down 4.1% year over year.
Its debt exceeds its cash by 63.80M GBP, a debt-to-equity ratio of 0.14. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 2980.00 GBp is 40.2% above the current price. The next earnings report is expected on 25 February 2027.